Nyxoah SA reports medical-technology developments tied to the Genio system, its patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for obstructive sleep apnea. Company news commonly covers financial and operating results, U.S. commercialization activity, regulatory status, manufacturing capacity, reimbursement references, investor conference participation, and the development and commercialization of OSA treatment alternatives.
Nyxoah also publishes regulated information for its Euronext Brussels and Nasdaq securities, including transparency notifications, shareholder-meeting materials, voting-right disclosures, and bond-related capital-structure notices.
Nyxoah SA (Euronext Brussels: NYXH) announced the issuance of 60,000 new shares on June 23, 2021, due to the exercise of subscription rights. The company's capital is now EUR 3,808,073.64. The total number of voting rights is 22,167,609, all of which are ordinary shares. Furthermore, various warrants, including 91 from 2013, 365 from 2016, 319 from 2018, and 550,000 from 2020, provide additional rights to subscribe to further shares.